Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis

Area of Science:

• Immunology
• Endocrinology
• Neuroimmunology

Background:

• Leptin, a hormone from fat cells, plays a role in immune and autoimmune conditions.
• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.

Purpose of the Study:

• To investigate how blocking leptin's effects can protect mice from experimental autoimmune encephalomyelitis (EAE), an animal model of MS.
• To elucidate the molecular mechanisms underlying leptin's influence on EAE.

Main Methods:

• Utilizing anti-leptin antibodies or a soluble leptin receptor chimera to block leptin in SJL/J mice.
• Inducing EAE using proteolipid protein peptide PLP(139-151).
• Assessing clinical scores, disease progression, relapse rates, T cell proliferation, cytokine profiles, and molecular markers like Foxp3, p27, ERK1/2, and STAT6.

Main Results:

• Leptin blockade, administered before or after EAE onset, significantly improved clinical outcomes, including reduced severity and relapses.
• Neutralizing leptin suppressed T cell proliferation specific to PLP(139-151) and shifted cytokine secretion towards a Th2/regulatory profile.
• Leptin antagonism led to increased expression of forkhead box p3 (Foxp3) in CD4 T cells and impaired downregulation of p27, accompanied by enhanced ERK1/2 and STAT6 phosphorylation.

Conclusions:

• Leptin blockade offers a protective effect against EAE by modulating T cell responses and immune profiles.
• The findings suggest a novel molecular mechanism for leptin's role in autoimmune diseases like MS.
• Leptin antagonism presents a potential therapeutic strategy for MS and related autoimmune disorders.